EFFECT OF DAPAGLIFLOZIN THERAPY ON SERUM URIC ACID IN TYPE 2 DIABETIC PATIENTS

Abstract

ABSTRACT
INTRODUCTION: Diabetes mellitus (DM) is a complicated chronic glucose metabolic disorder.
Primary defect is the insulin insufficiency. OBJECTIVE: Analyze and determine the effects of
dapagliflozin on serum uric acid in type 2 diabetic patients. STUDY DESIGN: Comparative cross
sectional study. PLACE AND DURATION: Suleman Roshan Medical College from January
2019 to December 2020. METHODS: A sample of 200 diabetics; divided into controls 100 taking
oral hypoglycemic drugs (OHD) and 100 cases taking OHD+ Dapagliflozin was selected by nonprobability convenient sampling. Blood glucose (FBG & RBG), A1C, BUN, creatinine and serum
uric acid were performed at baseline and 12 weeks of therapy. Data was collected and saved in a
pre – structured proforma. Data was analyzed on Statistic software (ver 18.0) using Student`s ttest for continuous variables. Data was analyzed at 95% CI (P≤ 0.05). RESULTS: FBG, RBG,
A1C and Uric acid were decreased in both control and cases however decrease was highly
significant in dapagliflozin group. Serum uric acid in control group A at baseline was 7.6±1.3
mg/dl that decreased to 7.3±3.1mg/dl. However, uric acid shows significant decrease in cases
group B, from baseline 7.7±1.7 mg/dl to 4.3±1.1 mg/dl after 12 weeks dapagliflozin therapy.
CONCLUSION: Dapagliflozin therapy significantly reduces the serum uric acid along with
improvement of glycemic status.